Thomas Patrick Kelly Sells 11,250 Shares of Deciphera Pharmaceuticals Inc (NASDAQ:DCPH) Stock

Share on StockTwits

Deciphera Pharmaceuticals Inc (NASDAQ:DCPH) CFO Thomas Patrick Kelly sold 11,250 shares of Deciphera Pharmaceuticals stock in a transaction on Tuesday, August 13th. The shares were sold at an average price of $41.27, for a total transaction of $464,287.50. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.

Thomas Patrick Kelly also recently made the following trade(s):

  • On Wednesday, June 19th, Thomas Patrick Kelly sold 177 shares of Deciphera Pharmaceuticals stock. The shares were sold at an average price of $25.00, for a total transaction of $4,425.00.
  • On Monday, June 3rd, Thomas Patrick Kelly sold 2,100 shares of Deciphera Pharmaceuticals stock. The shares were sold at an average price of $25.20, for a total transaction of $52,920.00.
  • On Wednesday, May 22nd, Thomas Patrick Kelly sold 1,473 shares of Deciphera Pharmaceuticals stock. The shares were sold at an average price of $25.06, for a total transaction of $36,913.38.

Shares of DCPH stock opened at $36.30 on Friday. The firm has a fifty day simple moving average of $23.11 and a two-hundred day simple moving average of $24.33. The company has a debt-to-equity ratio of 0.01, a quick ratio of 7.26 and a current ratio of 7.26. Deciphera Pharmaceuticals Inc has a 12 month low of $18.55 and a 12 month high of $42.99.

Deciphera Pharmaceuticals (NASDAQ:DCPH) last announced its quarterly earnings results on Friday, August 2nd. The company reported ($0.56) EPS for the quarter, beating the Zacks’ consensus estimate of ($1.12) by $0.56. The business had revenue of $25.00 million for the quarter, compared to the consensus estimate of $20.00 million. As a group, analysts predict that Deciphera Pharmaceuticals Inc will post -4.29 earnings per share for the current year.

DCPH has been the subject of a number of recent research reports. SunTrust Banks boosted their price target on shares of Deciphera Pharmaceuticals to $60.00 and gave the company a “buy” rating in a research note on Wednesday. Deutsche Bank initiated coverage on shares of Deciphera Pharmaceuticals in a research note on Thursday, July 18th. They set a “buy” rating and a $42.00 price target for the company. Piper Jaffray Companies boosted their price target on shares of Deciphera Pharmaceuticals from $50.00 to $55.00 and gave the company an “overweight” rating in a research note on Monday, June 3rd. They noted that the move was a valuation call. Zacks Investment Research upgraded shares of Deciphera Pharmaceuticals from a “sell” rating to a “hold” rating and set a $26.00 price target for the company in a research note on Monday, August 5th. Finally, ValuEngine lowered shares of Deciphera Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Tuesday. Four equities research analysts have rated the stock with a hold rating and eight have given a buy rating to the stock. The stock has an average rating of “Buy” and a consensus price target of $47.90.

Institutional investors and hedge funds have recently bought and sold shares of the business. Bank of Montreal Can purchased a new position in Deciphera Pharmaceuticals during the 2nd quarter worth $28,000. BNP Paribas Arbitrage SA boosted its holdings in Deciphera Pharmaceuticals by 61,033.3% during the 1st quarter. BNP Paribas Arbitrage SA now owns 1,834 shares of the company’s stock worth $43,000 after acquiring an additional 1,831 shares during the last quarter. Tower Research Capital LLC TRC purchased a new position in Deciphera Pharmaceuticals during the 2nd quarter worth $64,000. JPMorgan Chase & Co. boosted its holdings in Deciphera Pharmaceuticals by 89.2% during the 2nd quarter. JPMorgan Chase & Co. now owns 4,057 shares of the company’s stock worth $95,000 after acquiring an additional 1,913 shares during the last quarter. Finally, Morgan Stanley boosted its holdings in Deciphera Pharmaceuticals by 214.8% during the 2nd quarter. Morgan Stanley now owns 7,864 shares of the company’s stock worth $177,000 after acquiring an additional 5,366 shares during the last quarter. 59.10% of the stock is currently owned by hedge funds and other institutional investors.

Deciphera Pharmaceuticals Company Profile

Deciphera Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops drugs to enhance the lives of cancer patients by addressing key mechanisms of drug resistance that limit the rate and durability of response of various cancer therapies. The company's lead drug candidate is DCC-2618, which is in Phase III trial for the treatment of gastrointestinal stromal tumors; and that is in Phase I trial for treating advanced systemic mastocytosis, gliomas, melanoma, NSCLC/germ cell/penile, and soft tissue sarcomas.

Read More: Price Target

Insider Buying and Selling by Quarter for Deciphera Pharmaceuticals (NASDAQ:DCPH)

Receive News & Ratings for Deciphera Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Deciphera Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Keybank National Association OH Purchases Shares of 15,561 Silgan Holdings Inc.
Keybank National Association OH Purchases Shares of 15,561 Silgan Holdings Inc.
Keybank National Association OH Acquires New Stake in CBIZ, Inc.
Keybank National Association OH Acquires New Stake in CBIZ, Inc.
Keybank National Association OH Grows Stock Position in Antero Midstream GP LP
Keybank National Association OH Grows Stock Position in Antero Midstream GP LP
Keybank National Association OH Trims Stake in Vanguard Value ETF
Keybank National Association OH Trims Stake in Vanguard Value ETF
Keybank National Association OH Purchases 2,905 Shares of iShares Edge MSCI USA Value Factor ETF
Keybank National Association OH Purchases 2,905 Shares of iShares Edge MSCI USA Value Factor ETF
Keybank National Association OH Lowers Stake in TransUnion
Keybank National Association OH Lowers Stake in TransUnion


© 2006-2019 Ticker Report